Aims: Surgical site infections contribute to morbidity and mortality after surgery.
| INTRODUCTION
Despite routine antibiotic prophylaxis, surgical site infections (SSI) remain a feared complication after cardiac surgery. They are associated with significant morbidity and mortality, prolonged hospital stay, and exorbitant healthcare costs. 1 The reported total incidence of sternal wound infections after cardiac surgery ranges from 1 to 8%
accounting for an in-hospital mortality of up to 25%. (MIC: %T > MIC) after a single dose of the antibiotic. 4 For β-lactam,
we usually target at least 50% (50%T > MIC).
Cefuroxime (CXM), a second-generation cephalosporin has been successfully used for SSI prophylaxis in cardiac surgery. 5 Traditionally, cephalosporin antibiotics have been administered as separate single bolus infusions, which provide cyclical peaks and troughs in plasma concentration. However, for maximized bactericidal potency the duration during which concentrations exceed the MIC of the underlying pathogen 4-8 times appears to require optimization. 6 In this context, it can be speculated that the mode of administration could play an important role, assuming that continuous infusion may lead to prolonged target site concentrations above the corresponding MIC. Recently, Roberts et al 7 and Abdul-Aziz et al 8 showed decreased hospital mortality and higher success rates after continuous infusion compared to bolus infusion of β-lactam antibiotics in severely septic patients. However, no data of tissue concentrations of CXM are available to date comparing the 2 modes of CXM administration in patients undergoing cardiac surgery.
We tested the hypothesis that higher surgical site concentration will be reached over time by continuous administration of CXM during heart surgery that might improve infection prophylaxis without increasing the cephalosporin dose. We therefore compared 2 different regimens (bolus vs continuous infusion) of prophylactic administration of CXM in patients undergoing elective cardiac surgery. To support our hypothesis, we assessed the treatment effect by describing the corresponding medians with the dispersion of the data as well as the interquartile ranges (IQRs), a measure of uncertainty.
| METHODS
The study was carried out at the Division of Cardiothoracic and 
| Patients
Twelve male and female patients aged >19 years scheduled for elective cardiac surgery on cardiopulmonary bypass (CPB), were randomly allocated either to bolus (group A, n = 6) or to continuous (group B, n = 6) CXM administration. Exclusion criteria were: coexisting renal, hepatic or infectious diseases treated with β-lactam antibiotics or erythromycin prior to the start of the trial as well as prior medication with phenylbutazone, probenecid, acetazolamide or sodium bicarbonate, history of pseudomembranous colitis, haemodialysis or haemofiltration, previous cardiac surgery, combined procedures such as valve repair and coronary artery bypass graft (CABG) surgery or aortic aneurysm repair and known allergy or hypersensitivity against CXM. As use of the internal mammary artery as a bypass vessel during the CABG surgery impairs antibiotic penetration into the presternal tissue we primarily focused on patients scheduled for valve surgery. 9 The recruitment profile is depicted as a CONSORT flow diagram in Figure 1 .
| Anaesthesia, cardiopulmonary bypass and surgical procedure
Anaesthetic management, surgical procedure and CPB were carried out as previously described. 10 Further details on the demographic data, surgical procedure, duration of surgery, aortic cross-clamp time, duration of CPB, total fluid balance and intensive care treatment of both study groups are given in Table 1 .
| Experimental design
Microdialysis is an established technique at our department to measure antibiotic concentrations in the interstitial fluid (ISF). The detailed
What is already known about this subject
• First or second generation cephalosporines are successfully used to prevent surgical site infection after heart surgery.
• Continuous administration of antibiotics provides higher plasma concentrations.
• No data on tissue concentrations during continuously administered cefuroxime are available yet.
What this study adds
• We report plasma and tissue concentrations of cefuroxime after bolus and continuous infusion in patients undergoing elective cardiac surgery.
• Tissue concentrations were measured by the microdialysis technique.
• Continuous cefuroxime infusion provides higher tissue levels over a prolonged period. methodology has been previously described. 11 In short, for this study we used a flexible microdialysis probe (CMA 70, Microdialysis AB, Stockholm, Sweden) with a membrane length of 20 mm and a molecular mass cut-off of 20 000 Dalton. All probes were inserted and calibrated after induction of anaesthesia.
The insertion of the probes was performed under sterile conditions. One microdialysis probe was introduced into skeletal muscle of the thigh and a second probe into the subcutaneous adipose layer of the thigh. Before insertion, the surface of the skin was punctured using a 20-gauge intravenous cannula. The steel stylet was then removed and inappropriate intravascular placement checked by negative aspiration after which the dialysis probe was advanced within the plastic cannula. Afterwards, the plastic cannula was removed, leaving the probe in the appropriate layer under the surface of the skin. The microdialysis system was connected and perfused with 0.9% saline solution at a flow rate of 1.5 μL min −1 using a microinfusion pump Microdialysis samples for determination of antibiotic concentrations were collected in both groups in a similar manner: the corresponding intervals were 20 minutes during the first 2 hours, 30 minutes during the following 2 hours, in 1-hour intervals during the 2 hours thereafter, and in 2-hour intervals during the final 6 hours.
Microdialysis sampling was terminated 12 hours after the first IV CXM infusion.
Plasma samples were drawn in parallel to microdialysis samples.
Sampling of plasma was terminated 32 hours after the first IV CXM administration in both groups. All samples were stored at −80°C until further analysis.
| In vitro experiment to determine the recovery rate of the microdialysis probes for cefuroxime
Three calibration solutions containing 5 μg mL −1 , 30 μg mL −1 and 60 μg mL −1 CXM were tested sequentially starting with the lowest concentration. These microdialysis probes were perfused with Ringer's lactate at a constant flow (1.5 μL min −1 ). The dialysates were collected in 20 min intervals. The temperature of the calibration solution was measured during the whole procedure and was ). Thus, we showed prior to the study that: (1) CXM does not adhere to the probes; and (2) CXM diffusion via the membrane of the probe is almost optimal.
| Calibration of the microdialysis system
For determination of relative recovery, the microdialysis probes were calibrated in vivo in each experiment according to the retrodialysis method. 12 The principle of this method is based on the fact that the diffusion process is quantitatively equal in both directions through the semipermeable membrane. Therefore, CXM was included in the perfusion medium for probe calibration at 30 μg mL −1 , and the disappearance rate (delivery) through the membrane was calculated subsequently for each individual microdialysis probe. The in vivo recovery value was calculated as follows:
2.6 | Analysis of plasma and microdialysis samples
Concentrations of CXM in plasma and microdialysis samples were quantified using HPLC with detection at 274 nm according to the method of Signs et al. 13 Proteins in plasma samples were precipitated with an equal volume of an ice-cold mixture of methanol, containing the internal standard cefazoline and 0.1 M sodium acetate pH 5.2.
After centrifugation at 1500 g for 10 minutes the clear supernatant was used for analysis. Microdialysis samples were injected directly.
The lower limit of quantitation was 1 mg L −1 and the relative standard error (imprecision) was between 2.7% (100 mg L −1 plasma) and 8.5%
(1 mg L −1 microdialysis sample). Protein binding was determined with a microcentrifugation system (Centrifree, Millpore, Austria) using the above method for the determination of CXM. Median recovery was 100% in group A vs 91% in group B for muscle tissue and 100% in group A vs 99% in group B for subcutaneous tissue (not significant). The individual median recovery was used for calculation of individual tissue concentrations.
Main pharmacokinetic parameters for plasma, free plasma, muscle and subcutaneous tissue for both groups are presented in Table 2 in subcutaneous tissue and 32 mg L −1 in muscle tissue were reached at 65 and 40 minutes, respectively. The discrepancy between tissue peak concentrations that are given in Table 2 and Figure 3 respectively can be explained as follows. C 1max was calculated for every individual patient as well as T 1max and AUC. While C 1max values given in Table 2 represent the median of the patients true C 1max , values in Figure 3 represent the actual median value that was calculated at the time of each predesigned measurement. Therefore, the differences result from the difference in the time to reach C 1max in each patient. Consequently, Figure 3 and Table 2 do not show identical numbers. Regarding pharmacokinetic parameters, AUC of the total plasma, free plasma as well as subcutaneous CXM concentrations, were significantly higher (P < 0.05) with continuous administration (Table 2 ). This was also the case for C max of subcutaneous tissue, whereas no group difference was found for C max of intramuscular tissues despite a numerically greater C max in group B. In contrast, the mode of administration (bolus vs continuous) did not affect tissue/plasma AUC ratio, which indicates similar penetration of CXM into muscular and subcutaneous tissue. Accordingly, the ratio AUC tissue/plasma was comparable between groups. CXM was able to penetrate quickly into both tissues with a T 1max being reached within 65 minutes for both intermittent and continuous application ( Table 2) .
Another important pharmacokinetic parameter is the T > MIC, particularly for β-lactam antibiotics and especially for such a short-acting drug as CXM. The corresponding relationship between the T > MIC for free plasma, subcutaneous and muscular tissues are depicted in Table 3 . Graphical evaluation of the respective cefuroxime concentrations over time for each patient has been used to determine the percentage of time > MIC. As shown in Table 3 
| DISCUSSION
The current exploratory study is the first to compare plasma and tissue concentrations of prophylactically administered CXM in patients undergoing elective cardiac surgery with CPB. We tried to determine whether continuous administration of CXM might be superior to intermittent dosing.
Antibiotic prophylaxis aims to achieve MICs exceeding those recommended for the suspected pathogens in all body compartments, i.e. in the intravascular, intracellular and interstitial space. Since the primary infection mostly affects the interstitial compartment, high interstitial antibiotic concentrations should to be provided. Our trial revealed that despite administration of an equal cumulative dose over 24 hours (i.e. 4.5 g CXM) %T > MIC in plasma and tissue is shorter when CXM is given as 1.5 g bolus 3 times a day instead of a bolus of 1.5 g followed by 3 g CXM via continuous infusion. Statistically significant differences between the AUC of total and free plasma CXM concentrations could be demonstrated between groups (P = .026). In subcutaneous tissue AUC was higher (P = .041) when CXM was administered continuously. We also found significantly higher values (P = .026) for C max in subcutaneous tissue.
The observed differences between the AUC of the respective plasma concentrations is not unexpected as continuous administration achieves constantly higher AUC plasma values compared to an intermittent infusion ( Figure 2) . 10, 11 Free concentrations of CXM in the ISF were lower than free plasma concentrations for the entire length of our experiment, which also was as expected. 10, 11 Due to the technically highly demanding microdialysis technique intraoperative data are extremely rare. Pojar et al 15 Table 4 ).
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As previously mentioned, the percentage of time tissue concen- , and 8% for 16 mg L −1 (Table 3) . This means that via continuous infusion of CXM free drug concentration achieves at least 83%T > MIC that should be sufficient for the treatment of most causative Gram-positive cocci.
There are some limitations of our study that should be mentioned.
First, the group size is small, which is due to the difficulty to include matching patients undergoing similar procedures with a comparable duration on CPB. A further limitation was the slightly different time course in the administration of the antibiotic between groups. Nevertheless, both groups received the same amount of antibiotic within 24 hours. In addition, statistical significance alone, which either confirms or rejects the underlying hypothesis, does not necessarily indicate clinical relevance especially when small groups are studied.
The degree of uncertainty of the estimates and thus the potential clinical impact may better be appreciated in Figures 2 and 3 that incorporate IQRs. 14 Nevertheless, larger studies need to be performed to test for clinical outcome.
In conclusion, our findings demonstrate that higher plasma concentrations and longer time periods above MIC in muscle and still has to be determined. Independent of the chosen regimen it may be prudent to administer CXM 60 minutes prior to skin incision in order to guarantee adequate tissue concentrations at the beginning of surgery since maximum interstitial drug concentrations were frequently reached only after 60 minutes following the first infusion.
